<DOC>
	<DOC>NCT02269319</DOC>
	<brief_summary>The purpose of this study is to determine whether MRX-I is as safe and effective as Linezolid in the treatment of adult patients with acute bacterial skin and skin structure infections</brief_summary>
	<brief_title>MRX-I Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Linezolid</mesh_term>
	<criteria>Patients with systemic signs of infection diagnosed with acute bacterial skin and skin structure infection (ABSSSI) Diagnosed with Cellulitis/ erysipelas, major cutaneous abscess, or wound infections Uncomplicated skin infections Severe sepsis or septic shock ABSSSI solely due to gramnegative pathogens Prior systemic antibiotics within 96 hours of randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>ABSSSI</keyword>
	<keyword>MRX-I</keyword>
	<keyword>Acute Bacterial Skin and Skin Structure Infections</keyword>
</DOC>